ALVO Alvotech Biopharmaceuticals: Enterprise Value to EBITDA Ratio
Alvotech relies on European capacities, which minimizes trade conflict risks. The company's current EV/EBITDA trend reflects market dynamics where the 36.36 mark serves as a relevant indicator. The integration of biosimilars into healthcare systems expands distribution opportunities. However, international patent protection and the complexities of drug registration across different countries remain constraining factors for global growth.
Comprehensive metric breakdowns and analytics for alvotech.com (ALVO)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
ALVO - Company Net Income|Future Profit Alvotech|ALVO - Market Price to Net Income Ratio|Forward P/E Multiple Alvotech|ALVO - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Alvotech Biopharmaceuticals|ALVO - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Alvotech|ALVO - Earnings per share for the trailing year|Quarterly EPS earnings growth alvotech.com|ALVO - Earnings growth in current year|Net earnings per share growth forecast for next year Alvotech
Fundamental company analysis:ALVO (Alvotech Corp)
Geopolitical risks and patent disputes in biopharmaceuticals directly impact the capital expenditures and operational efficiency of Alvotech (ALVO). The company's trend EV/EBITDA level compares the total enterprise value with earnings before interest and taxes, enabling an assessment of the cash flow's ability to service debt, where any sharp fluctuations on the chart signal a critical shift in financial stability.
Who Alvotech competes with
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Liquidia Inc. LQDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Galapagos NV (GLPG)|ANIP (anipharmaceuticals.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple MNKD (MannKind)|EV/EBITDA Multiple Amphastar Pharmaceuticals Inc AMPH|PCRX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SPRY: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TBPH (Theravance Biopharma) - Enterprise Value to EBITDA Ratio|AQST (aquestive.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization scPharmaceuticals, Inc.|Company Value to EBITDA Tectonic TECX|Enterprise Value to EBITDA Ratio TNXP (Tonix Pharmaceuticals Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio SXTC|EV/EBITDA Multiple EPRX (Eupraxia Pharmaceuticals Inc.)|bioharvest.com (BHST) - Company Value to EBITDA|eXoZymes - EV/EBITDA Multiple|Oramed Pharmaceuticals (ORMP) - Enterprise Value to EBITDA Ratio|ENTX: EV/EBITDA Multiple|MindWalk Therapeutics - Business Value to Operating Income Before Depreciation|ABVC (ABVC BioPharma) - EV/EBITDA Multiple|EV/EBITDA Multiple cumberlandpharma.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Quantum BioPharma (QNTM)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FGEN (FibroGen Inc)|Telomir Pharma - Enterprise Value to EBITDA Ratio|Rani Therapeutics Holdings - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SNYR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Rallybio Corporation|lexariabioscience.com (LEXX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio PULM (Pulmatrix Inc)|PTHL (Pheton Holdings Limited) - EV/EBITDA Multiple|APM: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple LYRA|EV/EBITDA Multiple impactbiomedinc.com (IBO)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TNF Pharmaceuticals, Inc. TNFA|Business Value to Operating Income Before Depreciation YCBD|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Altamira Therapeutics (CYTO) - Enterprise Value to EBITDA Ratio|LIPO: EV/EBITDA Multiple|optinose.com (OPTN) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio PIRS|PROC: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Petros (PTPI)|QLI - Company Value to EBITDA|Acelyrin, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio TFFP (tffpharma.com)
